Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients

Area of Science:

• Biochemistry
• Pharmacology
• Genetics

Background:

• Cystinosis is a severe inherited metabolic disorder characterized by lysosomal cystine accumulation.
• Lifelong cysteamine bitartrate therapy is essential but often limited by frequent dosing and gastrointestinal side effects, impacting patient adherence.
• Optimizing cysteamine delivery is crucial for improving long-term outcomes in cystinosis management.

Purpose of the Study:

• To compare the efficacy of immediate-release cysteamine (IR-cysteamine) versus encapsulated delayed-release cysteamine (EC-cysteamine) in cystinosis patients.
• To evaluate the pharmacokinetic profiles and impact on cystine levels of different cysteamine formulations.
• To identify potential improvements in cysteamine treatment for enhanced patient quality of life.

Main Methods:

• Analysis of cystine and cysteamine levels in 17 patients on IR-cysteamine and 6 patients on EC-cysteamine.
• Pharmacokinetic assessment, including Tmax and Tmin, for both cysteamine formulations.
• Evaluation of gastrointestinal side effects and overall patient quality of life.

Main Results:

• EC-cysteamine demonstrated a near-ideal delayed-release pharmacokinetic profile with longer Tmax and Tmin, leading to fewer fluctuations in cystine levels.
• IR-cysteamine exhibited a higher Cmax, correlating with significant gastrointestinal side effects like nausea, vomiting, halitosis, and lethargy.
• Reduced dosing frequency (2-3 times daily) with EC-cysteamine improved patient quality of life.

Conclusions:

• EC-cysteamine offers a more favorable pharmacokinetic profile and improved tolerability compared to IR-cysteamine for cystinosis treatment.
• The enhanced adherence and reduced side effects associated with EC-cysteamine can significantly improve the quality of life for cystinosis patients.
• EC-cysteamine presents a viable, cost-effective alternative for patients lacking access to approved delayed-release formulations.